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RSV is amajor causeofhospitalizationof infants less than2years
of age [1]. Like its human counterpart, bovine respiratory syncytial
virus (BRSV) is a major cause of calf morbidity and mortality [2].
Calves less than 1 year of age are particularly susceptible to the
disease [3]. Maternal antibodies against respiratory syncytial virus
do not prevent infection in calves but antibodies seem to decrease
the severity of infection [4–6].
Furthermore, BRSV is one of the viruses contributing to bovine
respiratory disease complex [7]. Protection against BRSV afforded
by vaccination has been described and numerous vaccines are
licensed and widely used in the field [8–10]. However, exacer-
bation of respiratory disease has been induced in calves and in
infants vaccinated with formalin-inactivated BRSV vaccine [11,12].
In mice, enhanced disease has an immunopathological basis, char-
acterized by polarized type 2-helper (TH2) response. Increased IL-4
production has been associated with pulmonary histopathology
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) is a major cause of respiratory disease in both cattle and young children.
ccines against bovine (B)RSV, incomplete protection and exacerbation of
ccurred. In order to circumvent these problems, calves were vaccinated
known to be a major target of CD8+ T cells in cattle. This was performed
tein boost strategy. The results showed that DNA vaccination primed a
se, as indicated by both a lymphoproliferative response and IFN- pro-
enhanced after protein boost. After challenge, mock-vaccinated calves
ions and viral replication in the lungs. In contrast, calves vaccinated by
lasmid DNA and protein exhibited protection against the development of
l replication in the BAL fluids and the lungs. The protection correlated to
d not to the antibody response.
© 2008 Elsevier Ltd. All rights reserved.
and eosinophilia [13–15]. In calves, enhanced pathology has been
associated with elevated IgE titers and marked eosinophilia, sug-
gesting a TH2-mediated immune response [16–18]. In addition,
some authors have reported high mortality in calves subsequent
to the use of inactivated vaccine in the field [19,20]. There is thus a
need for protective vaccines, able to confer protection in neonates,
even in the presence of maternal antibodies and lacking disease
exacerbating side effects.
It has previously been shown that the F and G surface glycopro-
teins, and the N protein, are the major protective antigens of BRSV
[21]. Neutralizing antibodies to the F protein can mediate protec-
tion [22]. However, serum antibodies provide greater contribution
in reducing BRSV induced lower respiratory disease thanupper res-
piratory tract virus shedding [4,23]. The cell-mediated immunity is
also a critical parameter in the outcome of RSV infection [24,25].
The F, P, G, M, M2 and N proteins are antigenic targets recognized
bybovineCD8+ Tcells, the latter twoproteinsbeingalso specific tar-
gets formurine (M2protein)ormurineandhuman (Nprotein)CD8+
T cells [26–29]. These cells constitute the major lymphocyte sub-
population in the respiratory tract of calves recovering from BRSV
infection and depletion of those cells also induces delayed virus
clearance from the lungs and nasopharynges in calves [23,30,31].
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In mice, diminished CTL activation and migration to the lungs by
treatment with anti-LFA-1 delayed viral clearance [32]. Further-
more, priming of the RSV-specific CD8+ response suppressed the
eosinophilia induced after challenge of animals vaccinatedwith the
G glycoprotein [33].
DNA vaccination is an effective way of generating humoral and
cell-mediated response [34]. Intramuscular vaccination of mice
with plasmid DNA expressing the F or G proteins of RSV has shown
to induce a strong TH1 response and to reduce the viral load in the
lungs after RSV challenge, without inducing enhanced pulmonary
inflammatory response or eosinophilia [35,36]. However, it is gen-
erally recognized that DNA vaccines are often less effective in large
animals than in mice [37]. Improvement of the immune response
can be achieved by boosting animals previously vaccinated with
plasmid DNA with inactivated vaccine. This approach has suc-
cessfully been used to protect calves against bovine herpesvirus-1
(BoHV-1) challenge [38]. This strategy was also successfully used
in a previous BRSV experiment. Calves vaccinated with codon-
optimized plasmid DNA expressing the F and N BRSV proteins and
boosted with an inactivated commercial vaccine were protected
against clinical signs, gross pneumonic lesions and virus replica-
tion [39]. In that study, the humoral and cell-mediated immune
responses were primed by DNA injection and enhanced by the
protein boost. They reduced the clinical signs and the virus repli-
cation after BRSV challenge. The use of the F protein of RSV in a
prime–boost protocol also represents an interesting strategy for
early life immunization [40].
The purpose of the work presented here was to investigate
the protection of calves against BRSV, by focusing mainly on the
Fig. 1. Polyacrylamide gel electrophoresis of the N protein, purified from recombi-
nant baculovirus infected Sf9 insect cells (lane 2) and a molecular weight marker
(Sigma, lane 1). The proteins were stained with Coomassie blue.(2008) 4840–4848 4841
stimulation of the BRSV cell-mediated immunity. Therefore, a com-
bination of plasmid and protein vaccination was performed with
the N protein as immunogen. The protection conferred by this vac-
cination scheme was evaluated after BRSV challenge.
2. Materials and methods
2.1. Expression of the N protein
The pcDNA3 plasmid expressing synthetic DNA sequence cod-
ing for the ORF of the N protein of BRSV (pNsyn) has been
described elsewhere [39]. Large scale plasmid DNA was purified
from transformed TOP 10 bacteria cells by affinity chromatography
on anion-exchange resin (Plasmid Giga kit, Qiagen).
The purified N protein was obtained from a recombinant bac-
ulovirus expressing the coding sequence of the N protein of BRSV
strain RB94. Briefly, the N gene was cloned in the pBlueBacHis2A
vector (Invitrogen). Recombinant baculovirus expressing theNpro-
tein (BacN) was obtained after transfection of Sf9 insect cells with
the recombinant plasmid and purification of the -galactosidase-
expressing plaques as recommended by the manufacturer. Sf9 cells
were infectedwith BacN at amoi of 2. Cellswere harvested 48–72h
pi, when at least 95% of the cells were lysed, washed with PBS and
resuspended in Tris–HCl 20mMpH7.9, NaCl 0.5M, Imidazole 5mM
buffer. The 6His-tagged N protein was purified on Ni-NTA resin
(Qiagen) in batch, as recommended by the manufacturer. The pro-
tein concentration was determined by BCA protein assay (Pierce)
according to the manufacturer’s recommendations. As expected, a
protein of 43kDa was purified and analyzed by PAGE (Fig. 1) [41].
Prior to immunization, QuilA adjuvant was added to the N protein
at a final concentration of 1mg/ml.
2.2. Cell culture and virus
The BRSV RB90 virus was grown on calf primary kidney cells in
Minimal Eaglemedium (MEM, GIBCO BRL) supplementedwith 10%
fetal calf serum, 10mg/ml gentamycin and 106 IU penicillin.
Challenge inoculum’s consisted in lung lavage fluid of a calf
collected after intratracheal inoculation with the BRSV strain
VRS3761, as described previously [39,42]. This inoculum contained
103.4TCID50/ml and was free of bovine viral diarrhea virus, bovine
herpesvirus-1, bovine parainfluenza virus-3, bovine coronavirus,
bovine adenovirus-5, endotoxins, bacteria and mycoplasmas. Back
titration confirmed the amount of virus inoculated.2.3. Study design
Fourteen cross-bred dairy calves between 4 and 6 weeks of age
were randomly allocated in 4 experimental groups of 3 or 4 ani-
mals and housed in 3 identically conditioned stables. All calves
were shown to be seronegative for BRSV, BoHV-1 and Bovine viral
diarrhea virus at the start of the experiment.
As shown in Table 1, 7 calveswere vaccinated twice at a 4weeks
interval (day 0 and 29)with 500g of pNsynplasmidDNA in saline.
The first vaccine dose was injected intramuscularly and the second
dose was administrated intradermally in 4 sites in the neck. Seven
other calves were subjected to the same protocol, but with the
pcDNA3 control plasmid. Four weeks after the second DNA admin-
istration (day 60), respectively, 4 and 3 calves injected with the
pNsyn and the control plasmids were subjected to intramuscular
injectionof 300gof purifiedNprotein, adjuvantedwithQuil A in a
2mlvolume. Theother calveswere treatedwith saline. Threeweeks
after the third vaccination (day 80), all the calves were challenged
with the BRSV 3761 strain by intratracheal (10ml) injection com-
bined to intranasal nebulization (5ml). The calves were examined
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Table 1
Experimental design
Group n Vaccination
Day 0/V1 Day 29/V2
Mock 4 pcDNA3 pcDNA3
pNsyn 3 pNsyn pNsyn
Npur 3 pcDNA3 pcDNA3
pNsyn-Npur 4 pNsyn pNsyn
daily after challenge for the following clinical signs: cough, nasal
discharge, anorexia, depression, rectal temperature and respiratory
rate.
Sera and heparin treated blood were collected prior to each vac-
cination, on the day of challenge and on days 6 (day 86) and 12 after
challenge (day 92) for examination of humoral and cell-mediated
responses. Bronchoalveolar lung (BAL) fluids were collected every
2 or 3 days from day 3 before to day 11 after challenge by instil-
lation and aspiration of 50ml of PBS as described previously [39].
On days 6 and 12 after challenge, one or two calves of each group
were euthanized. Lungs were excised immediately after euthana-
sia. Macroscopic lesions were recorded to score the extent of
pneumonic consolidation and seven pieces of tissue from right cra-
nial (cranial and caudal portions), middle and caudal lobes were
excised.
2.4. Lymphocyte proliferation assay (LPA)
Heparinised blood samples were ten-fold diluted in RPMI 1640
medium (Gibco, Belgium) supplemented with 2mM glutamine,
5×10−5 M -2-Mercaptoethanol, 100U/ml of gentamycin and
2.5g/ml fungizone. Two hundred l of diluted blood samples
were incubated during 6 days with 20l of BRSV antigen (Son-
icated and heat-inactivated culture supernatant of primary calf
kidney cells infected with RB90 virus, containing 105TCID50/ml),
or 20l of control antigen (Sonicated and heat-inactivated cul-
ture supernatant of primary mock-infected calf kidney cells). After
the 6-days incubation, 0.8Ci of methyl [3H] thymidine in 25l
RPMI 1640 medium was added to each well. Cells were collected
after a subsequent 18h incubation using a cell harvester and
radioactivity incorporated into the DNA was measured by liquid
scintillation counting (Betaplate, Pharmacia, Sweden). The results
were expressed as stimulation indexes (SI) corresponding to the
number of c.p.m. obtained with the BRSV antigen divided by the
number of c.p.m. obtained with the control preparation. The SI cut-
off of 2.4 was determined as the mean+3 standard deviations of
the SI values of all animals before vaccination.
2.5. IFN- assay
The gamma-interferon (IFN-) production was measured after
a 24-h in vitro stimulation of 1ml of heparinised blood with 20l
of BRSV or control antigen. The amounts of IFN- in the plasma
were quantified by ELISA with the Bovine -interferon EASIA kit
(Biosource Europe). The results were expressed as stimulation
indexes (SI) corresponding to the OD obtained with the BRSV anti-
gen divided by the OD obtained with the control preparation. The
cut-off SI value of 1.6was calculated as 3 standard deviations above
the mean SI value of all calves before vaccination.
2.6. Serological response
Serum samples were collected from all calves before each vac-
cination, on the day of challenge and on days 6 and 12 after
the challenge. They were subjected to the indirect immunoflu-(2008) 4840–4848
Challenge n calves Euthanized
Day 60/V3 Day 80 Day 86 Day 92
Saline BRSV 2 2
Saline BRSV 1 2
Npur BRSV 1 2
Npur BRSV 2 2
orescence test as described previously [43]. Briefly, the sera
were serially three-fold diluted starting from a 1/15 dilution and
they were incubated on both slides covered with BRSV infected
and with non-infected primary kidney cells. After a washing
step, the cells were incubated with FITC-conjugated rabbit anti-
bovine IgG and observed on a fluorescence microscope. Slides
were examined without any information on the group assign-
ments.
Local humoral priming was investigated by testing the presence
of N-specific IgG and IgA in the BAL after challenge. IgG antibod-
ies were determined in an indirect ELISA, using the purified N
protein as coating antigen. After incubation with two-fold dilu-
tions of LBA, starting from 1:10, the test was revealed by using
HRP-conjugated rabbit anti-bovine serum and TMB as substrate.
N-specific IgA antibodies were determined essentially as described
[44]. Briefly, plates were coated with Mab against bovine IgA
(Cedi-diagnostics, The Netherlands) and incubated with two-fold
dilutions of LBA starting from1:2. Reactionwith the purifiedNpro-
tein was revealed by using biotin-conjugated bovine serum against
BRSV, HRP-conjugated streptavidin and TMB.
2.7. Viral replication
The viral load in the BAL fluids and in the lungs was investigated
by quantitative real-time RT-PCR. Briefly, for each animal, pieces
of approximately 1 cm3 of each lung lobe were mixed together in
10ml of PBS using an Ultraturrax homogenizer. Two hundred l of
BAL fluid and 200l of homogenate extractswere subjected to RNA
extraction and cDNA synthesis as described previously [45]. Real-
timeRT-PCRspecific forBRSVand forbovinebeta-actin (ACTB)were
performed along with the corresponding standard curves allowing
quantification. The results were expressed as the number of BRSV
RNA copies per 103 ACTB copies in the BAL fluids and per 106 ACTB
copies in the lungs.
2.8. Histopathology
A necropsy sample of lesion was taken in each pulmonary
lobe. The samples were stored in 10% neutral buffered forma-
lin, embedded in paraffin, sectioned at 5m and stained with
hematoxylin and eosin for histologic examination. Slides were
then examined without any information on the group assign-
ments.
2.9. Statistics
The data collected in the 4 groups were compared by one-way
analysis of variance and Tukey’s test with a family error rate of
0.05. Logarithmic transformation was applied to the lymphocyte
proliferation SI, the IFN- SI and the IFI titers in order to fulfil the
conditions of variances homogeneity (checked by Bartlett’s test)
and normality (checked by Ryan and Joiner’s test).
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significantly from the mean of the mock-vaccinated group.
experiment, while one animal of the Npur group show a SI above
the cut-off on day 92.
3.2. BRSV-specific antibody response
BRSV-specific antibody response was measured by indirect
immunofluorescence (Fig. 4). The pNsyn priming elicited low levels
of antibody that increased either after the protein boost in all ani-
mals of the pNsyn–Npur group or after the challenge in animals of
the pNsyn group. Injection of the N protein alone also induced spe-
cific seroconversion. At the time of challenge, the mean antibody
titers of the 3 vaccinated groups were not significantly different
from each other (p>0.05). However, the antibody titers of the 3
vaccinatedgroupswere significantlyhigher than thoseof themock-
vaccinated group (p<0.05). Seroconversion of themock-vaccinated
animals was only observed 12 days after challenge, consistent with
a priming effect of the challenge.Fig. 2. In vitro BRSV-specific lymphoproliferation following vaccination and chal-
lenge. Blood samples were tested at the time of each vaccination (day 0, 29 and 60),
on the day of challenge (week 80) and on days 6 and 12 after challenge (days 86 and
92). The results are expressed as stimulation index. The bars represent the mean
value for each group and the vertical bars represent the standard deviation of the
means. The horizontal dashed bar represents the cut-off value. The stars indicate
the means that differ significantly from the mean of the mock-vaccinated group
(p<0.05).
3. Results
3.1. BRSV-specific cellular response
BRSV-specific lymphoproliferative response was detected in 4
of the 7 calves vaccinated twice with pNsyn plasmid (Fig. 2). While
injectionof theNproteinwasnot able to inducedetectable lympho-
proliferative response in non-primed animals, this protein boosted
the responses in calves previously vaccinated with pNsyn. After
the boost, all the calves of the pNsyn–Npur group had a stimu-
lation index above the cut-off and a considerable enhancement
of the BRSV-specific proliferative response. At that time, 2 out of
the 3 calves of the pNsyn group still had a SI value above the
cut-off. On day 80, the mean SI value of the pNsyn–Npur group
was significantly different from the mean SI value of the 3 other
groups (p<0.05) and it remained higher than those of both the
mock-vaccinated and Npur groups after challenge (p<0.05). The
BRSV challenge did not induce a detectable response in the mock-
vaccinated group. In contrast, the lymphoproliferative responses of
the calves vaccinated with pNsyn were enhanced and the mean
SI value of this group was significantly different from those of the
control group and the group vaccinated with the N protein alone
(p<0.05). Twelve days after challenge, the calves of the Npur group
also showed low levels of proliferative response.
After 2 plasmid vaccinations, the IFN- SI of all animals
remained below the cut-off (Fig. 3). However, after the protein
boost, the animals subjected to the pNsyn plasmid and the N pro-
tein vaccinations displayed significant IFN- production compared
to the 3 other groups (day 80, p<0.05). The animals vaccinated
with pNsyn alone had also been primed for IFN- production, as
shown by significant SI values 1 week after the challenge (day 86).
On day 86, the IFN- SI of the 2 groups vaccinated with pNsyn were
significantly different from those of the 2 other groups (p<0.05).
The mock-vaccinated groups remained negative till the end of theFig. 3. In vitro IFN- production after BRSV antigenic stimulation. Blood samples
were tested before at the time of each vaccination (days 0, 29 and 60), at challenge
(day 80) and at 6 and 12 days after challenge (days 86 and 92). The results are
expressed as stimulation index. The bars represent the mean value for each group
and the vertical bars represent the standard deviation of the means. The horizontal
dashed bar represents the cut-off value. The stars indicate the means that differFig. 4. BRSV-specific antibody response. Sera taken at the time of each vaccination
(days 0, 29 and 60), on the day of challenge (day 80) and on days 6 and 12 after
challenge (days 86 and 92) were analyzed by indirect immunofluorescence. The
results are expressed as the log3 of the last positive dilution and they are presented
as the mean value for each group. The vertical bars represent the standard deviation
of the means.
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of the calves vaccinated with pNsyn alone and in the calves primed
with pNsyn and boosted with the N protein. Two out of the 3 calves
vaccinatedwith theNproteinalonewerealsoprotected. In contrast,
BRSV RNA was detected in the lungs of all the mock-vaccinated
animals.
4. Discussion
Numerous advantages have been described for the use of DNA
vaccines. They theoretically combine the efficacy of live vaccines
and the safety afforded by the inactivated vaccine [46]. They can
circumvent the inhibitory effects of maternal antibodies [47] andFig. 5. Total RNA was extracted from BAL fluids collected 3 days before and 3, 5, 7
and 11 days after challenge. The viral load was examined by quantitative real-time
RT-PCR and expressed as the number of BRSV RNA copies per 103 ACTB RNA copies.
The bars represent themean value for each group and the vertical bars represent the
standarddeviationof themeans. Thestars indicate themeans thatdiffer significantly
from the mean of the control group.
The priming of a local response in the different vaccinated
groups was investigated by measuring N-specific IgG and IgA in the
BAL after challenge. None of the animals exhibited N-specific IgG
response 3 days before challenge, and all the animals of the mock-
and-pNsyn-vaccinated groups remained negative till the end of the
experiment. IgG antibodies were detected in the Npur group from
day 5 to 11 after the challenge with a maximum mean titer of 1/20
at D+5. In the pNsyn–Npur group, positive animals were recorded
from 3 to 7 days after the challenge, with a maximum mean titer
of 1/30, 5 days after the challenge (data not shown). In contrast,
no N-specific IgA response was detected in the BAL, whatever the
vaccinated group (data not shown).
3.3. Protection against BRSV challenge
3.3.1. Clinical signs
After challenge, no fever or increase of the respiratory rate were
recorded. Three animals of themock-vaccinated group experienced
a mild cough lasting for at least 1 day after challenge, but this was
not considered as significant (data not shown).
3.3.2. Viral RNA load in the BAL
The replication of challenged BRSV was followed in the BAL flu-
ids collected every 2 or 3 days by quantitative real-time RT-PCR
(Fig. 5). As expected, all the calves were negative 3 days before the
challenge. Viral RNA was detected in the mock-vaccinated calves
from day 3 after the challenge till the end of the experiment. How-
ever, at day 11, the infection has almost resolved, as the viral load
in the BAL fluids was about 100 copies of viral RNA. Similar kinetic
was observed in the calves vaccinated with the N protein, excepted
that the viruswas cleared on day 11. All animals primedwith pNsyn
showed lower BRSV RNA copy numbers in their BAL fluids than the
2 other groups. Indeed, for each animal and at each time point, the
viral load was below 200 RNA copies/103 ACTB copies. Also, each
animal was positive at maximum 2 successive time points and all
calves had cleared the virus on day 11 post-challenge. However, the
great individual variability and the low number of animals in each
group prevented the differences between the 2 groups vaccinated
with pNsyn and the 2 other groups to be statistically significant,
except on day 5 after challenge (p<0.05).
3.3.3. Postmortem examination
One or 2 animals of each group were killed on day 6 after chal-
lenge while the 2 remaining animals of each group were killed on
day 12.(2008) 4840–4848
The lungs were examined and the presence of pneumonic con-
solidationwas recorded for each lobe. The number of affected lobes
in each group is summarized in Table 2. In the mock-vaccinated
group, all the calves showed lesions in the caudal part of the cra-
nial lobe, and in the middle and accessory lobes. The cranial part
of the cranial lobe was affected in 3 calves and the caudal one in
2 calves. In contrast, in the group vaccinated with both pNsyn and
the N protein, only one calf showed one spot of consolidation in the
cranial lobe (cranial part) and another in the caudal lobe. This group
was significantly different from mock-vaccinated group (p<0.05).
The 2 other groups gave intermediate results (8 affected lobes/15),
and the 6 animals showed lesions in the cranial part of the cranial
lobe. However, the difference with the control group was not sta-
tistically supported. These lesions were also less severe in extent in
these 2 groups than in the control group with the exception of one
animal vaccinated with the N protein. All the lobes of this animal
were affected and the extent of the lesionswas comparable to those
observed in the mock-vaccinated group.
Histological examination of the lungs revealed typical BRSV
lesions. Histopathological lesions of the bronchi and bronchioles
including lymphoid peribronchial cuffing (Fig. 6a and b), lymphoid
infiltration, hyperplasia and metaplasia of the epithelium with
desquamation and the presence of syncytial cells in the lumen
(Fig. 6c and d). Infiltration of mononuclear inflammatory cells
with consolidation and emphysema were recorded in the alveoli
(Fig. 6e and f). However, irrespective of the slaughtering time post-
challenge (day 6 or day 12), the lesions were less severe and more
limited in the group vaccinatedwith pNsyn andNpur (Fig. 6a, c and
e) than in the 3 other groups (Fig. 6b, d and f).
The viral replication in the lungs was analyzed by quantitative
real-time RT-PCR (Table 3). No BRSV RNA was detected in the lungstheyprime theTH1componentof the immune response [48]. This is
of particular interest for overcoming the TH2biaswhen vaccinating
neonates against BRSV [49].
Several studies described the vaccination of mice with plas-
mids expressing the F or G glycoproteins [35,50,51]. These 2
antigens have also been tested as vaccine candidates in calves.
A plasmid expressing the G glycoprotein afforded only partial
reduction of viral shedding after challenge [52,53]. More recently,
Table 2
Macroscopic pneumonic lesions
Mock Npur pNsyn pNsyn–Npur
Cranial: cranial part 3/4 3/3 3/3 1/4
Cranial: caudal part 4/4 1/3 1/3 0/4
Middle 4/4 2/3 3/3 0/4
Caudal 2/4 1/3 1/3 1/4
Accessory 4/4 1/3 0/3 0/4
Total 17/20 8/15 8/15 2/20
For each animal, all the pulmonary lobes were examined for the presence of pneu-
monic consolidation. The ratios of animals presenting lesions are indicated for each
lobe. The total number of affected lobes in each group is also presented.
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(a) AbFig. 6. Pulmonary histopathology after BRSV challenge in the pNsyn–Npur vaccina
vaccinated group (f). (b) Lymphoid peribronchial cuffing (arrows). (d) Epithelial hype
(f) Consolidation of the alveoli with infiltration of mononuclear inflammatory cells.
Absence of infiltration of mononuclear inflammatory cells.
DNA vaccine encoding the BRSV fusion protein induced significant
protection against the virus challenge, by reducing the nasopha-
ryngeal excretion of the virus and the extent of gross pneumonic
lesions. However, complete protection against BRSV was not con-
ferred [54]. Finally, DNA immunization of infant rhesus monkeys
or young calves against both the BRSV F and nucleocapsid (N)
proteins stimulated both humoral and cell-mediated immunity
against the virus and reduced viral replication, clinical signs and
pulmonary lesions after challenge [39,55]. Reports describing the
use of the N protein are rather scarce. However, N was shown to
be a major target of the immune response against RSV. Vaccination
of mice with recombinant vaccinia virus encoding the (H)RSV N
protein induced partial resistance [56,57]. Similarly, immunization
of young calves with a recombinant vaccinia virus expressing the
BRSV N protein induced non-neutralizing antibodies and primed
the BRSV-specific proliferative response and IFN- production that
resulted in reduction of viral replication in the upper and lower
respiratory tract [21,28]. Overall, these data suggest that the protec-oup (a, c and e) and in the other groups: mock-vaccinated group (b and d), pNsyn-
a andmetaplasia (arrows)with desquamation of the cells in the lumen (arrowhead).
sence of lymphoid peribronchial cuffing. (c) Absence of epithelial proliferation. (e)tion afforded by theNproteinmight be largelymediated by cellular
immunity.
The efficacy of DNA immunization against the N protein alone
had never been studied before the present study. The purpose of
this work was thus first to stimulate the cellular immune response
using a DNA vaccine and then to enhance this response with a pro-
teic boost. Therefore, we used of the nucleocapsid (N) protein of
BRSV in a “prime–boost” vaccination strategy and we compare it to
the use of DNA or protein vaccination alone.
In the present study, we show that both cellular and humoral
arms of the immune responsewere stimulated by the vaccine com-
bination. Injection of either pNsyn or Npur induced a BRSV-specific
humoral response. The neutralizing activity of the antibodies was
not investigated here, but antibodies against the N protein were
shown non-neutralizing by others [21]. At the time of challenge,
however, there was no significant difference between the vacci-
nated groups. Furthermore, vaccination did not prime for a local
N-specific IgA response. This is in accordance with the results
4846 Letellier C et al. / Vaccine 26Table 3
The viral loads in the lungs were examined by conducting quantitative real-time
RT-PCR on total RNA extracted from homogenates of pieces from the different pul-
monary lobes
Experimental group Calf BRSV RNA copies/106 ACTB RNA copies
Mock
6601 5.5×103
6604 2.0×104
6621 5.2×105
6628 1.2×103
Npur
6615 –
6622 6.8×104
6626 –
pNsyn
6596 –
6610 –
6624 –
pNsyn–Npur
6603 –
6611 –
6612 –
6620 –
(–) Not detected.
published by others. Indeed, vaccination with a recombinant vac-
cinia virus expressing the N protein induced local IgG1 but not IgA
response [21]. A lymphoproliferative response was only induced
in calves that received the pNsyn plasmid. This response was
increased when calves were boosted with the N protein, resulting
in significantly higher stimulation index compared to the 3 other
groups. In contrast, only the prime–boost combination induced the
production of IFN-.
After the challenge, the clinical and virological protections
were evaluated. No clinical signs were recorded, even in the
mock-vaccinated animals. This is in contrast with the previous
experiment, where the same stock of BRSV 3761 was used [39]. The
reasons are unclear but could be linked to the age or the genetic
background of the animals [58]. However, the virus replicated in
the respiratory tract of the mock-vaccinated animals, the high-
est viral load being observed in the BAL on day 5 post-infection.
At autopsy, the viral load in the lungs was as high as previously
described [39] and gross pneumonic as well as histopathologi-
cal lesions were observed. After injection of the N protein, 2 out
the 3 calves were protected against BRSV replication in the lungs.
However, high viral loads were detected in the BAL fluids, and
protection against pneumonic lesions was only partial. DNA vac-
cination alone was able to protect against viral replication in the
lungs and to strongly reduce the viral replication in the BAL but
the calves were not totally protected against the development of
gross pneumonic lesions. The presence of lung consolidations at
autopsy indicates the spreadof thevirus in the lungs. Indeed,patho-
logical changes have been shown to appear when replication of
BRSV spreads to the alveoli and may continue after clearance of
the virus [59]. In contrast, protection against both the viral replica-
tion in the lungs and the gross and histological pneumonic lesions
was afforded by the combination of DNA and protein vaccination,
suggesting that infectious virus was cleared before infecting the
alveoli.
The role of the cellular immunity in the protection against RSV
and the pathogenesis induced by the virus is controversial. Bovine
IFN- has been shown to induce a TH1 response, characterized by
IgG2 production [60]. On one hand, both CD4+ and CD8+ T cells can
eliminate the virus but they also cause immunopathology in mice
[61]. IFN- was identified as a key molecule involved in both the
virus control and the immunopathology induced by CD8+ T cells
[62]. In mice, TH1 and TH2 biased T cell responses could either
co-exist or down regulate each other [14,63]. On the other hand,
impaired viral clearance and enhanced disease observed after vac-(2008) 4840–4848
cinationwith FI vaccine have been correlatedwith decreased IFN-
production [64]. Formulation of FI-BRSV with CpG ODN resulted in
increased IFN- secretion and reduction of both gross lung pathol-
ogy and viral replication in calves and inmice [65,66]. Furthermore,
Modified Live vaccine induced cellular immunity, in particular
secretion of IFN- by peripheral blood leukocytes, appeared to be a
more consistent correlate of protection than pre-challenge serum
antibody [67]. Our data are consistent with these results. Indeed,
the only animals that were protected against both viral replica-
tion in the lungs and the development of macroscopic lung lesions
resulting of BRSV challenge were those that had been vaccinated
successively with pNsyn and N protein and that exhibited signifi-
cant IFN- production at the time of the challenge.
Injection of the purified N protein, mixed with Quil A did not
induce measurable lymphoproliferative response. This was not
anticipated because other authors showed that insect cells infected
with recombinant baculovirus expressing the F protein and mixed
with Quil A stimulate the cellular-mediated immune response in
lambs [68]. However, as baculovirus has been shown as stimulator
of immune response, this could contribute to the overall effect of
the immunogen [69]. In our experiment, the N protein was never-
theless able to prime for a lymphoproliferative response, detected
after BRSV challenge, and this might be attributed to a TH1 trigger-
ing of the adjuvant. After vaccination with the N protein, 2 out of
the 3 calves were protected against viral replication in the lungs.
Virus was detected in the lungs of the remaining calf (calf 6622).
Interestingly, this calf had also higher viral load in BAL fluids and
more extended lesions of the lungs compared to the 2 other calves
of this group. The 3 calves showed identical serological responses.
However, when the lymphoproliferative response was individually
examined on blood collected 6 days after challenge, the SI was
below 1 for calf 6622 and of about 3 for the 2 other calves (data
not shown). We hypothesize that the development of pulmonary
lesions and the viral replication in the lungs were correlated with
the absence of cell-mediated immunity.
The prime–boost strategy used herewas superior toDNAor pro-
tein vaccination alone in term of protection for large animals. This
is in accordance with the results published by others. Indeed, this
strategy was recently shown to induce stronger humoral immune
response and better protection against BVDV in cattle compared to
immunization with DNA or protein alone [70]. Boosting DNA vac-
cinated mice with recombinants vectors can elicit strong CD4 and
CD8 immune responses [71]. Furthermore, it has been shown that
the longevityof T-cell stimulationwashigher afterDNAprime–MLV
boost than after MLV vaccination alone against BoHV-1 in cattle
[72]. Boosting CD8 response with inactivated virus or recombinant
proteins is more controversial. While inactivated viral boost was
shown to enhance the CD4 and antibody responses but not the CD8
response against severe acute respiratory syndrome coronavirus in
mice, other authors described an enhancement of CD8+ CTL and
CD4+ T-helper cells against HIV after a protein boost in nonhuman
primates [73,74]. Here also, although the cytotoxic T cell response
was not investigated, increased lymphoproliferative response and
IFN- production were observed, suggesting an enhancement of
the cellular response after the protein boost.
In conclusion, the results presented here show protection
against BRSV replication in the lung and against lung pathology
after nucleocapsid-based DNA prime–protein boost protocol. This
vaccination strategy elicited both humoral and cellular immune
responses. The observed protection correlated with the lympho-
proliferative response and the interferon- production. The results
also confirm the efficacy of the prime–boost strategy in a large ani-
mal model. This strategy is promising for the protection against
RSV in cattle and it could also open perspectives for vaccinating
young infants aswell. Furtherwork should beperformed to confirm
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